Norlela Sukor

Prof. Dr. Norlela Sukor


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MNMitsuhide Naruse
Mitsuhide Naruse
MMMasanori Murakami
Masanori Murakami
TKTakuyuki Katabami
Takuyuki Katabami
TKTomaz Kocjan
Tomaz Kocjan
Mirko Parasiliti-CaprinoMirko Parasiliti-Caprino
Mirko Parasiliti-Caprino
TSTomoko Suzuki
Tomoko Suzuki
Objective: Primary aldosteronism (PA) is one of the most frequent causes of secondary hypertension. Although clinical practice guidelines recommend a diagnostic process, details of the steps remain incompletely standardized. Design: In the present SCOT-PA survey, we have investigated the diversity of approaches utilized for each diagnostic step in different expert centers through a survey using Google questionnaires. A total of 33 centers from 3 continents participated. Results: We demonstrated a prominent diversity in the conditions of blood sampling, assay methods for aldosterone and renin, and the methods and diagnostic cutoff for screening and confirmatory tests. The most standard measures were modification of antihypertensive medication and sitting posture for blood sampling, measurement of plasma aldosterone concentration (PAC) and active renin concentration by chemiluminescence enzyme immunoassay, a combination of aldosterone-to-renin ratio with PAC as an index for screening, and saline infusion test in a seated position for confirmatory testing. The cutoff values for screening and confirmatory testing showed significant variation among centers. Conclusions: Diversity of the diagnostic steps may lead to an inconsistent diagnosis of PA among centers and limit comparison of evidence for PA between different centers. We expect the impact of this diversity to be most prominent in patients with mild PA. The survey raises 2 issues: the need for standardization of the diagnostic process and revisiting the concept of mild PA. Further standardization of the diagnostic process/criteria will improve the quality of evidence and management of patients with PA.

14 September 2023 in Hormones
Verified
Journal Article
Closed access
PDF file
HLHuai Heng Loh
Huai Heng Loh
QLQuan Hziung Lim
Quan Hziung Lim
WKWaye Hann Kang
Waye Hann Kang
YYYee Hway Ann @ Anne Yee
Yee Hway Ann @ Anne Yee
MYMei Ching Yong
Mei Ching Yong
NSNorlela Sukor
Norlela Sukor

9 June 2025 in European Journal of Endocrinology
Verified
Journal Article
Closed access
MMMasanori Murakami
Masanori Murakami
MNMitsuhide Naruse
Mitsuhide Naruse
HKHiroki Kobayashi
Hiroki Kobayashi
Mirko Parasiliti-CaprinoMirko Parasiliti-Caprino
Mirko Parasiliti-Caprino
FBFabio Bioletto
Fabio Bioletto
TKTomaz Kocjan
Tomaz Kocjan
Objective: Severity classifications are essential for many diseases to prioritize patient management tasks such as diagnosis, treatment, and follow-up. Primary aldosteronism (PA), a common cause of secondary hypertension, lacks a standardized severity scale despite generally requiring invasive diagnostics like adrenal venous sampling (AVS). This study aimed to develop a global expert consensus-based classification for PA severity to improve clinical decision-making. Methods: A panel of 45 international experts from 40 centers across four continents used the Delphi method to create a consensus severity classification for PA. This classification was then applied retrospectively to 2593 PA patients from 26 centers to assess its association with the disease subtype. Results: After four rounds, the Primary Aldosteronism Severity Classification (PASC), which integrates biochemical and clinical parameters including serum potassium, blood pressure, and basal plasma aldosterone concentration, was established. Primary Aldosteronism Severity Classification classifies PA into mild (3 and 4 points), moderate (5-7 points), and severe (8 and 9 points). Among the cohort from 26 centers, 13.9%, 63.0%, and 23.1% were classified as mild, moderate, and severe, respectively, aligning with lateralized subtype prevalence rates of 14.7%, 44.6%, and 72.6%. Conclusion: Primary Aldosteronism Severity Classification is a newly developed simplified, semi-quantitative classification of PA severity. The correlation between PASC and lateralized PA subtype supports its potential to provide graded recommendations of AVS prior to surgical indication in each patient.

29 September 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
HLHuai Heng Loh
Huai Heng Loh
NSNorlela Sukor
Norlela Sukor
Both primary aldosteronism and obstructive sleep apnea are well-known causes of hypertension and contribute to increased cardiovascular morbidity and mortality independently. However, the relationship between these two entities remains unclear, with studies demonstrating contradictory results. This review aims to collate and put into perspective current available research regarding the association between primary aldosteronism and obstructive sleep apnea. The relationship between these two entities, clinical characteristics, clinical implications, outcomes of treatment, potential causal links and mechanisms are hereby presented.

1 October 2011 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
NSNorlela Sukor
Norlela Sukor

23 January 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
NSNorlela Sukor
Norlela Sukor
SSSarat Sunthornyothin
Sarat Sunthornyothin
TTThang V Tran
Thang V Tran
TTTri Juli Tarigan
Tri Juli Tarigan
LMLeilani B Mercado-Asis
Leilani B Mercado-Asis
TPTroy H Puar
Troy H Puar
Context: While guidelines have been formulated for the management of primary aldosteronism (PA), following these recommendations may be challenging in developing countries with limited health care access. Objective: We aimed to assess the availability and affordability of health care resources for managing PA in the Association of Southeast Asian Nations (ASEAN) region, which includes low-middle-income countries. Methods: We instituted a questionnaire-based survey to specialists managing PA, assessing the availability and affordability of investigations and treatment. Population and income status data were taken from the national census and registries. Results: Nine ASEAN country members (48 respondents) participated. While screening with aldosterone-renin ratio is performed in all countries, confirmatory testing is routinely performed in only 6 countries due to lack of facilities and local assays, and cost constraint. Assays are locally available in only 4 countries, and some centers have a test turnaround time exceeding 3 weeks. In 7 countries (combined population of 442 million), adrenal vein sampling (AVS) is not routinely performed due to insufficient radiological facilities or trained personnel, and cost constraint. Most patients have access to adrenalectomy and medications. In 6 countries, the cost of AVS and adrenalectomy combined is more than 30% of its annual gross domestic product per capita. While most patients had access to spironolactone, it was not universally affordable. Conclusion: Large populations currently do not have access to the health care resources required for the optimal management of PA. Greater efforts are required to improve health care access and affordability. Future guideline revisions for PA may need to consider these limitations.